-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Benzinga·10/09/2026 18:02:34
Listen to the news
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.